As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...
June 27, 2006 — The US Food and Drug Administration (FDA) has approved a pill-swallowing cup to facilitate ingestion of medications and vitamins in patients who have difficulty swallowing; an ...
HADLIMA™ (adalimumab-bwwd) injection, 40 mg/0.4 mL & 40 mg/0.8 mL is now interchangeable with all high- and low-concentration presentations (autoinjector, prefilled syringe, and single-dose vial) of ...
Humira (adalimumab) is a prescription drug that’s used to treat certain types of arthritis and other inflammation-related diseases. It comes as a liquid solution for injection under your skin. Humira ...
The Food and Drug Administration has granted an expanded interchangeable designation for Celltrion’s Yuflyma (adalimumab-aaty), now including prefilled syringe (40mg) and autoinjectors (40mg and 80mg) ...
Humira (adalimumab) is a prescription drug used for various conditions, including rheumatoid arthritis and plaque psoriasis. Mild side effects of the drug include injection site reactions, headache, ...
If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor. Starting July 1, alternatives to the ...
AbbVie GK, Eisai Co. and EA Pharma Co. have debuted the HUMIRA Pen, an auto-injector pen meant to help simplify self-injection. The product, which has a rounded pen-type body designed to help patients ...
NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved HUMIRA® (adalimumab) for the treatment of moderately to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results